High Purity CAS: 155141-29-0 Rosiglitazone Maleate CAS NO.155141-29-0

1. Hubei Jusheng Technology Co., Ltd.,  is a global chemical industry manufacturers and suppliers of pharmaceuticals and intermediates in China.

2. The yearly production capacity is 50000MT, 80% for export.We have a professinal export team. Both by Air and by Sea,we ensure that we meet the customer expectations with promptness.
3. Our company facing global High-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and Rare chemicals trade. Corey have well-equipped machine, strong technical force and considerate marketing team service.
4. We also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.  

Detailed Product Description


Rosiglitazone maleate
Synonyms: 5-((4-[2-(METHYL-2-PYRIDINYLAMINO)-ETHOXY]-PHENYL)-METHYLENE)-2,4-THIAZOLIDINEDIONE;5-{p-[2-(methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedione maleate;ROSIGLITAZONE MALEATE;RosiglitazoneTartrate;Avandi;BRL-49653c;RSIGLITAZONEMALEATE;5-(4-(2-(Methyl(pyridin-2-yl)aMino)ethoxy)benzyl)thiazolidine-2,4-dione Maleate
CAS: 155141-29-0
MF: C22H23N3O7S
MW: 473.5
Chemical Properties White To Off-White Solid
Usage Insulin sensitizer; binds to peroxisome proliferator activated receptor gamma (PPAR- γ).
Usage Thiazole alkanes antidiabetic drug
Package: 25kg/drum
Standard: enterprise Standard
Lead Time: Within 24 hours after receiving the payment
Delivery time:4-6 working days by Air for quantity less than 200kgs or 20 days By sea for quantity over than 250kg.
Certificates: ISO9001
Payment terms: , Money Gram, T/T


Rosiglitazone is a thiazolidinedione insulin sensitizer that activates PPARγ, decreasing blood glucose and insulin levels. Rosiglitazone exhibits anti-diabetic, anti-inflammatory, antioxidative, anticancer, anti-angiogenic, antihypertensive, and anti-fibrotic activities. In vivo, rosiglitazone decreases LPS-stimulated production of TNF-α, IL-1β, and IL-6 as well as activity of myeloperoxidase; it also inhibits activation of NF-κB, preventing mastitis. In multiple myeloma cells, rosiglitazone suppresses expression of HIF-1α and IGF-1, decreases activation of Aky, and Erk, and inhibits cell viability and proliferation. This compound also inhibits endothelin-1-induced vasoconstriction in a NO-dependent manner in animal models of pulmonary arterial hypertension. Additionally, rosiglitazone prevents activation of AP-1, production of collagen, and differentiation in fibroblasts.